About This Stock More About This StockReadReadReadReadRead
Merck KGaA And Pfizer Get FDA Approval Of Checkpoint Inhibitor "Avelumab" For Rare Merkel Cell Skin Cancer Therapy
Article By: Ari Zoldan
Wednesday, March 22, 2017 8:25 AM EDT
Specialty pharmaceuticals is a highly dynamic sector with robust stock valuations and an active mergers & acquisition market. One of the most attractive areas for investment is dermatology.
Article By: Sweta Killa
Monday, March 20, 2017 2:05 PM EDT
The initial sell-off came after Trump’s budget blueprint, which signaled higher regulatory costs for the sector and a cut in federal funding for medical research.
Article By: Lorimer Wilson
Monday, March 20, 2017 12:38 PM EDT
Just one week after Novartis scored a key approval for its CDK 4/6 cancer drug, Eli Lilly & Co. has announced that its long-awaited Phase III readout for its rival drug "abemaciclib" looks good albeit remaining far behind Pfizer in the CDK 4/6 game.